Seth Charatz, DO
Endocrinology, Diabetes & Metabolism · Rochester, NYNPI 1801833850
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $234,498 of the $266,146 with a category attached, or 88.1%. 10 manufacturers reported payments, led by Novo Nordisk at 46.2% of the total. Reporting peaked in 2019 at $86,544 and has fallen 77.1% since, to $19,824 in 2025. Among endocrinology, diabetes & metabolism clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 415 payments — averaging $641.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$123K
- Sanofi-aventis U.S. LLC$60K
- AstraZeneca$41K
- Johnson & Johnson$19K
- Boehringer Ingelheim$11K
- Lilly USA, LLC$10K
- plus $1K from 4 others
What the payments were for
- Consulting fees$13,6795%
- Speaking & faculty fees$234,49888%
- Travel & lodging$7,9163%
- Food & beverage$10,0334%
- Education$200%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 123 | $122,987 |
| Sanofi-aventis U.S. LLC | 57 | $59,799 |
| AstraZeneca | 90 | $41,224 |
| Johnson & Johnson | 40 | $19,073 |
| Boehringer Ingelheim | 33 | $11,234 |
| Lilly USA, LLC | 67 | $10,420 |
| Mannkind Corporation | 1 | $650 |
| IBSA Pharma Inc. | 1 | $500 |
| Amgen | 2 | $241 |
| Abbott | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$266,146 in reported general payments places this provider in the 95th percentile of 804 endocrinology, diabetes & metabolism providers in New York.
See all endocrinology, diabetes & metabolism providers in New York →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 1,097 | $1,459,684 |
| JardianceEmpagliflozin | 610 | $549,923 |
| MounjaroTirzepatide | 296 | $365,022 |
| FarxigaDapagliflozin Propanediol | 470 | $361,265 |
| TrulicityDulaglutide | 252 | $314,152 |
| MycapssaOctreotide Acetate | 13 | $169,868 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 64 | $159,221 |
| InvokanaCanagliflozin | 118 | $151,298 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 125 | $150,906 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 95 | $92,157 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 545 | $85,247 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 43 | $81,167 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 173 | $75,134 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 77 | $73,295 |
| Insulin Lispro Kwikpen U-100Insulin Lispro | 223 | $66,391 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Novolog | $122,987 | $1,537,7821,196 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog, Insulin Lispro | $10,420 | $694,486633 claims |
| Boehringer IngelheimJardiance, Synjardy Xr, Tradjenta | $11,234 | $581,500639 claims |
| AstraZenecaFarxiga | $41,224 | $361,265470 claims |
| Johnson & JohnsonInvokana, Invokamet | $19,073 | $161,578129 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33, Lantus | $59,799 | $155,475149 claims |
| AmgenProlia | $241 | $47,06929 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 804 endocrinology, diabetes & metabolism providers in New York.
Other endocrinology, diabetes & metabolism in Rochester
- Michael QuartuccioRochester$130K
- Robert BuschAlbany$2.7M
- Michael ShanikSmithtown$1.2M
- Ajay ChaudhuriBuffalo$888K
- Vinay KapoorManhasset$820K
- John BilezikianNew York$809K
- Barbara HirschManhasset$746K
- Martin GrajowerBronx$713K
- Anastasios ManessisNew York$656K
- Jonas LeibowitzYonkers$613K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.